Skip to main content

Advertisement

Table 2 Potential targets for breast cancer precise therapy

From: Cancer-associated adipocytes: key players in breast cancer progression

Agent Target In vitro effect Preclinical and clinical effects References
Cenicriviroc CCR2 Inhibitor of CCR2 Inhibition of monocyte recruitment, Prevent virus from entering into a human cell [137, 138]
Maraviroc CCR5 Inhibitor of CCR5 Blockade the HIV from entering macrophages and T cells [139]
Tocilizumab IL-6R Monoclonal antibody against IL-6R Hindering IL-6 from exerting its pro-inflammatory effects. [140]
Canakinumab IL-1β Monoclonal antibody against IL-1β Treatment of cryopyrin-associated periodic syndromes [141]
Infliximab TNF-α Monoclonal antibody against TNF-α Treatment of autoimmune diseases [142,143,144]
Bevacizumab (Avastin) VEGF Monoclonal antibody against VEGF-A Angiogenesis inhibitor [145]
AZD3695 MCT1 MCT1 inhibition Reduce tumor growth, Increase intra-tumor lactate [146]
Nivolumab PD-1 Monoclonal antibody against PD-1 Checkpoint inhibitor [147]
Durvalumab PD-L1 Monoclonal antibody against PD-L1 Blocking the interaction of PD-L1 with the PD-1 and CD80 (B7.1) molecules. [148]
Avelumab PD-L1 Monoclonal antibody against PD-L1 Blocking the interaction of PD-L1 binding to PD-1 [149]